Company intelligence / Profile preview

Ischemix, Inc.

Grafton, Massachusetts, United Statesischemix.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

CMX-2043, the company's lead compound for TBI, has demonstrated safety in over 400 patients in clinical trials with no reported serious adverse drug-related events. It has shown promising preclinical results in sensorimotor activity, cognition, memory, contusion volume, hyperactive behavior, and biochemical assays. The company received a $2.9 million award from the US Department of Defense to fund a Phase 1 study of CMX-2043 for TBI.[1][3]

Therapeutic areas: CardiovascularNeurologyNephrology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

CMX-2043

Partnerships

US Department of DefenseUS Army Medical Research and Development Command (USAMRDC)Combat Casualty Care Research Program (CCCRP)Medical Technology Enterprise Consortium (MTEC)

Beyond the preview

Go deeper on Ischemix, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ischemix, Inc..

Explore the full profile